SCHEMBL1534437

SCHEMBL1534437

CC(C)(C)OC(=O)NC1(c2ccc(-c3c(-c4ccccc4)oc4cc(C(N)=O)ccc4c3=O)cc2)CCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.41
AKT2 P31751 1/20 0.41
PLA2G2A P14555 1/20 0.37
PLA2G4A P47712 1/20 0.37
CYP3A4 P08684 4/20 0.36
CYP2C8 P10632 1/20 0.36
KIT P10721 1/20 0.35
IP6K1 Q92551 1/20 0.35
MAPT P10636 5/20 0.35
KDM4E B2RXH2 5/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
GAA P10253 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 7/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
TSHR P16473 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1534690 0.90 AKT1 (0.42) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1900768 0.89 AKT1 (0.42) AKT1AKT2CYP3A4CYP2C8KIT
SCHEMBL1534850 0.89 AKT1 (0.42) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1534534 0.88 AKT1 (0.45) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1534619 0.88 PLA2G2A (0.46) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1901791 0.88 PLA2G2A (0.46) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1534668 0.87 ALDH1A1 (0.48) AKT1AKT2CYP3A4MAPTKDM4E
SCHEMBL1534858 0.85 AKT1 (0.40) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1534541 0.85 AKT1 (0.40) AKT1AKT2PLA2G2APLA2G4ACYP3A4
SCHEMBL1534621 0.85 AKT1 (0.42) AKT1AKT2PLA2G2APLA2G4ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546376-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2013-10-01 US disclosed
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2012-09-20 US disclosed
EP-2473495-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2012-07-11 EP disclosed
WO-2011033265-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PLK1, MTOR AKT1 6/4885AKT2 4/4885PLA2G2A 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.